Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...

A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...

How do early-life exposures shape the infant skin microbiome and atopic dermatitis risk? New cohort data reveal key ...

Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive technology compared to those conceived naturally.

January 23, 2026 Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal ...